Yesterday, May 3, 2016, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $503.53 to $7,621,855.35. Highlighted Stocks Traded by Insiders: CVB Financial (CVBF) - FREE Research Report Vaccaro San, who is Director at CVB Financial, sold 22,520 shares at $17.24 on May 3, 2016. Following this transaction, the Director owned 221,957 shares meaning that the stake was reduced by 9.21% with the 22,520-share transaction. Oswalt Hal W, who is Director at CVB Financial, bought 1,500 shares at $17.25 on May 3, 2016. Following this transaction, the Director owned 19,500 shares meaning that the stake was boosted by 8.33% with the 1,500-share transaction. The shares most recently traded at $16.54, down $0.71, or 4.29% since the insider transaction. Historical insider transactions for CVB Financial go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 3,619
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 16,619
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 16,619

The average volume for CVB Financial has been 648,500 shares per day over the past 30 days. CVB Financial has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are down 0.47% year-to-date as of the close of trading on Tuesday. CVB Financial Corp. operates as the holding company for Citizens Business Bank that provides various banking and trust services for businesses, professionals, and individuals. It operates in two segments, Business Financial and Commercial Banking Centers, and Treasury. The stock currently has a dividend yield of 2.78%. The company has a P/E ratio of 17.3. Currently, there are no analysts who rate CVB Financial a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVBF - FREE

TheStreet Quant Ratings

rates CVB Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, expanding profit margins, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

CVB Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Integra Lifesciences Holdings (IART) - FREE Research Report

Gorelick Richard D., who is Corp VP, Gen Counsel & Sec at Integra Lifesciences Holdings, sold 4,000 shares at $70.72 on May 3, 2016. Following this transaction, the Corp VP, Gen Counsel & Sec owned 13,702 shares meaning that the stake was reduced by 22.6% with the 4,000-share transaction. Davis Robert T. Jr., who is Corp VP, Spc Surgica Solutions at Integra Lifesciences Holdings, sold 1,500 shares at $69.72 on May 3, 2016. Following this transaction, the Corp VP, Spc Surgica Solutions owned 13,844 shares meaning that the stake was reduced by 9.78% with the 1,500-share transaction. The shares most recently traded at $70.17, up $0.45, or 0.64% since the insider transaction. Historical insider transactions for Integra Lifesciences Holdings go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Integra Lifesciences Holdings has been 280,600 shares per day over the past 30 days. Integra Lifesciences Holdings has a market cap of $2.7 billion and is part of the health care sector and health services industry. Shares are up 3.94% year-to-date as of the close of trading on Tuesday. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has a P/E ratio of 478.4. Currently, there are 7 analysts who rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IART - FREE

TheStreet Quant Ratings

rates Integra Lifesciences Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Integra Lifesciences Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

XL Group (XL) - FREE Research Report

Hendrick Gregory, who is CEO, XL Reinsurance at XL Group, bought 8,000 shares at $32.43 on May 3, 2016. Following this transaction, the CEO, XL Reinsurance owned 130,738 shares meaning that the stake was boosted by 6.52% with the 8,000-share transaction. The shares most recently traded at $32.48, up $0.05, or 0.17% since the insider transaction. Historical insider transactions for XL Group go as follows:

  • 4-Week # shares bought: 15,300
  • 4-Week # shares sold: 33,659
  • 12-Week # shares bought: 15,300
  • 12-Week # shares sold: 33,659
  • 24-Week # shares bought: 15,300
  • 24-Week # shares sold: 33,659

The average volume for XL Group has been 2.2 million shares per day over the past 30 days. XL Group has a market cap of $9.4 billion and is part of the financial sector and insurance industry. Shares are down 17.05% year-to-date as of the close of trading on Tuesday. XL Group plc, through its subsidiaries, operates as an insurance and reinsurance company. The company provides property, casualty, and specialty products to industrial, commercial, professional, and insurance companies, as well as other enterprises worldwide. The stock currently has a dividend yield of 2.48%. The company has a P/E ratio of 7.8. Currently, there are 8 analysts who rate XL Group a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XL - FREE

TheStreet Quant Ratings

rates XL Group as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full

XL Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.